Study S000201

The Effect of Exenatide on Insulin Requirement, Weight and Inflammation in Obese Type 2 Diabetic Subjects on Insulin

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01154933
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: SINGLE
Status: COMPLETED
Enrollment: 24
Start: 2008-04
Primary completion: 2011-11
Lead sponsor: University at Buffalo
Conditions: Type 2 Diabetes
Interventions: DRUG:exenatide 5 mcg; DRUG:exenatide 10 mcg; DRUG:placebo
Results posted: TRUE

Registered primary outcomes

Fasting Insulin [after 24 hours fast at baseline and 12 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0024838	Exenatide Increases IL-1RA Concentration and Induces Nrf-2‒Keap-1‒Regulated Antioxidant Enzymes: Relevance to β-Cell Function. Dandona P, The Journal of clinical endocrinology and metabolism	2018	Randomized trial	PMID 29346597 DOI	cites ClinicalTrials.gov:NCT01154933; registry reference DERIVED:29346597